Challenges in Diabetic Macular Edema Management: An Expert Consensus Report

References

• Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281. doi:10.1016/j.diabres.2018.02.023
   PubMed Web of Science ®Google Scholar
• Bourne RRA, Jonas JB, Bron AM, et al.; Vision Loss Expert Group of the Global Burden of Disease Study. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections. Br J Ophthalmol. 2018;102(5):575–585. doi:10.1136/bjophthalmol-2017-311258.
   PubMed Web of Science ®Google Scholar
• Li JQ, Welchowski T, Schmid M, et al. Prevalence, incidence and future projection of diabetic eye disease in Europe: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35(1):11–23. doi:10.1007/s10654-019-00560-z
   PubMed Web of Science ®Google Scholar
• Kocur I, Resnikoff S. Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol. 2002;86(7):716–722. doi:10.1136/bjo.86.7.716
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz J, Coscas G. Diagnosis of macular edema. Ophthalmologica. 2010;224(Suppl 1):2–7. doi:10.1159/000315156
   PubMed Web of Science ®Google Scholar
• Barham R, El Rami H, Sun JK, Silva PS. Evidence-based treatment of diabetic macular edema. Semin Ophthalmol. 2017;32(1):56–66. doi:10.1080/08820538.2016.1228388
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222. doi:10.1159/000458539
   PubMed Web of Science ®Google Scholar
• García-Layana A, Figueroa MS, Arias L, et al. Clinical decision-making when treating diabetic macular edema patients with dexamethasone intravitreal implants. Ophthalmologica. 2018;240(2):61–72. doi:10.1159/000486800
   PubMed Web of Science ®Google Scholar
• Kim EJ, Lin WV, Rodriguez SM, Chen A, Loya A, Weng CY. Treatment of diabetic macular edema. Curr Diab Rep. 2019;19(9):68. doi:10.1007/s11892-019-1188-4
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Bellocq D, Bandello F, et al. First-line treatment algorithm and guidelines in center-involving diabetic macular edema. Eur J Ophthalmol. 2019;29(6):573–584. doi:10.1177/1120672119857511
   PubMed Web of Science ®Google Scholar
• Singh RP, Elman MJ, Singh SK, Fung AE, Stoilov I. Advances in the treatment of diabetic retinopathy. J Diabetes Complications. 2019;33(12):107417. doi:10.1016/j.jdiacomp.2019.107417
   PubMed Web of Science ®Google Scholar
• Acón D, Wu L. Multimodal Imaging in Diabetic Macular Edema. Asia Pac J Ophthalmol. 2018;7(1):22–27. doi:10.22608/APO.2017504
   Web of Science ®Google Scholar
• Liu G, Xu D, Wang F. New insights into diabetic retinopathy by OCT angiography. Diabetes Res Clin Pract. 2018;142:243–253. doi:10.1016/j.diabres.2018.05.043
   Web of Science ®Google Scholar
• Wong TY, Sun J, Kawasaki R, et al. Guidelines on Diabetic Eye Care: the International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. Ophthalmology. 2018;125(10):1608–1622. doi:10.1016/j.ophtha.2018.04.007
   PubMed Web of Science ®Google Scholar
• Kwan CC, Fawzi AA. Imaging and biomarkers in diabetic macular edema and diabetic retinopathy. Curr Diab Rep. 2019;19(10):95. doi:10.1007/s11892-019-1226-2
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology. 1987;94:761–774. doi:10.1016/s0161-6420(87)33527-4
   Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group: Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report No. 19. Arch Ophthalmol. 1995;113:1144–1155. doi:10.1001/archopht.1995.01100090070025
   Google Scholar
• Cunningham ET, Adamis AP, Altaweel M, et al.; Macugen Diabetic Retinopathy Study Group. A Phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112(10):1747–1757.
   PubMed Web of Science ®Google Scholar
• Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS; Macugen 1013 Study Group. A Phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology. 2011;118(6):1107–1118. doi:10.1016/j.ophtha.2011.02.045
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al.; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al.; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–1359. doi:10.1016/j.ophtha.2016.02.022.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al.; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 Phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. doi:10.1016/j.ophtha.2011.12.039.
   PubMed Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al.; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–2022. doi:10.1016/j.ophtha.2013.02.034.
   PubMed Web of Science ®Google Scholar
• Boyer DS, Nguyen QD, Brown DM, Basu K, Ehrlich JS; RIDE and RISE Research Group. Outcomes with as-needed ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE Trials. Ophthalmology. 2015;122(12):2504–2513.e1. doi:10.1016/j.ophtha.2015.08.006
   PubMed Web of Science ®Google Scholar
• Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–2254. doi:10.1016/j.ophtha.2014.05.006
   PubMed Web of Science ®Google Scholar
• Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100- week results from the VISTA and VIVID studies. Ophthalmology. 2015;122:2044–2052. doi:10.1016/j.ophtha.2015.06.017
   PubMed Web of Science ®Google Scholar
• Do DV, Nguyen QD, Vitti R, et al. Intravitreal aflibercept injection in diabetic macular edema patients with and without prior anti-vascular endothelial growth factor treatment: outcomes from the phase 3 program. Ophthalmology. 2016;123(4):850–857. doi:10.1016/j.ophtha.2015.11.008
   Web of Science ®Google Scholar
• Boyer DS, Faber D, Gupta S, et al.; Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31(5):915–923. doi:10.1097/IAE.0b013e318206d18c.
   PubMed Web of Science ®Google Scholar
• Callanan DG, Gupta S, Boyer DS, et al.; Ozurdex PLACID Study Group. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 2013;120(9):1843–1851. doi:10.1016/j.ophtha.2013.02.018.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121(12):2473–2481. doi:10.1016/j.ophtha.2014.07.002
   PubMed Web of Science ®Google Scholar
• Fraser-Bell S, Lim LL, Campain A, et al. Bevacizumab or Dexamethasone Implants for DME: 2-year Results (The BEVORDEX Study). Ophthalmology. 2016;123(6):1399–1401. doi:10.1016/j.ophtha.2015.12.012
   PubMed Web of Science ®Google Scholar
• Aroney C, Fraser-Bell S, Lamoureux EL, Gillies MC, Lim LL, Fenwick EK. Vision-Related quality of life outcomes in the bevordex study: a clinical trial comparing ozurdex sustained release dexamethasone intravitreal implant and bevacizumab treatment for diabetic macular edema. Invest Ophthalmol Vis Sci. 2016;57(13):5541–5546. doi:10.1167/iovs.16-19729
   Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al.; FAME Study Group. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626–635.e2. doi:10.1016/j.ophtha.2010.12.028.
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz J, Ashton P, Iezzi R, et al.; FAME Study Group. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology. 2014;121(10):1892–1903. doi:10.1016/j.ophtha.2014.04.019.
   PubMed Web of Science ®Google Scholar
• Baker CW, Glassman AR, Beaulieu WT, et al.; DRCRRetina Network. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA. 2019;321(19):1880–1894. doi:10.1001/jama.2019.5790.
   PubMed Web of Science ®Google Scholar
• Reznicek L, Cserhati S, Seidensticker F, et al. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment. Acta Ophthalmol. 2013;91(7):e529–536. doi:10.1111/aos.12153
   PubMed Web of Science ®Google Scholar
• Matsuda S, Tam T, Singh RP, et al. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. J Diabetes Complications. 2014;28(2):166–170. doi:10.1016/j.jdiacomp.2013.11.009
   PubMed Web of Science ®Google Scholar
• Zur D, Iglicki M, Busch C, Invernizzi A, Mariussi M, Loewenstein A; International Retina Group. OCT biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. Ophthalmology. 2018;125(2):267–275. doi:10.1016/j.ophtha.2017.08.031
   PubMed Web of Science ®Google Scholar
• Gerendas BS, Prager S, Deak G, et al. Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema. Br J Ophthalmol. 2018;102(2):195–203. doi:10.1136/bjophthalmol-2017-310483
   PubMed Web of Science ®Google Scholar
• Lee H, Kang KE, Chung H, Kim HC. Prognostic factors for functional and anatomic outcomes in patients with diabetic macular edema treated with dexamethasone implant. Korean J Ophthalmol. 2018;32(2):116–125. doi:10.3341/kjo.2017.0041
   PubMedGoogle Scholar
• Lee H, Kang KE, Chung H, Kim HC. Three-dimensional analysis of morphologic changes and visual outcomes in diabetic macular edema. Jpn J Ophthalmol. 2019;63(3):234–242. doi:10.1007/s10384-019-00657-8
   PubMed Web of Science ®Google Scholar
• Do DV, Cho M, Nguyen QD, et al. Impact of optical coherence tomography on surgical decision making for epiretinal membranes and vitreomacular traction. Retina. 2007;27(5):552–556. doi:10.1097/IAE.0b013e31802c518b
   Web of Science ®Google Scholar
• Sakamoto A, Nishijima K, Kita M, Oh H, Tsujikawa A, Yoshimura N. Association between foveal photoreceptor status and visual acuity after resolution of diabetic macular edema by pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol. 2009;247(10):1325–1330. doi:10.1007/s00417-009-1107-5
   PubMed Web of Science ®Google Scholar
• Alasil T, Keane PA, Updike JF, et al. Relationship between optical coherence tomography retinal parameters and visual acuity in diabetic macular edema. Ophthalmology. 2010;117(12):2379–2386. doi:10.1016/j.ophtha.2010.03.051
   PubMed Web of Science ®Google Scholar
• Maheshwary AS, Oster SF, Yuson RM, Cheng L, Mojana F, Freeman WR. The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema. Am J Ophthalmol. 2010;150(1):63–67.e1. doi:10.1016/j.ajo.2010.01.039
   Web of Science ®Google Scholar
• Dugel PU, Campbell JH, Kiss S, et al. Association between early anatomic response to anti-vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema: an independent analysis of protocol I study data. Retina. 2019;39(1):88–97. doi:10.1097/IAE.0000000000002110
   PubMed Web of Science ®Google Scholar
• Busch C, Fraser-Bell S, Zur D, et al.; International Retina Group. Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study. Acta Diabetol. 2019;56(7):777–784. doi:10.1007/s00592-019-01310-z.
   PubMed Web of Science ®Google Scholar
• Wykoff CC. Thresholds for initiating treatment of eyes with diabetic macular edema and good vision: consideration of DRCR.Net Protocol V Results. Ophthalmol Retina. 2019;3(11):917–919. doi:10.1016/j.oret.2019.07.007
   Google Scholar
• Wells JA, Glassman AR, Jampol LM, et al.; Diabetic Retinopathy Clinical Research Network. Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. JAMA Ophthalmol. 2016;134(2):127–134. doi:10.1001/jamaophthalmol.2015.4599.
   PubMed Web of Science ®Google Scholar
• Cantrell RA, Lum F, Chia Y, et al. Treatment patterns for diabetic macular edema: an intelligent research in sight (IRIS®) registry analysis. Ophthalmology. 2020;127(3):427–429. doi:10.1016/j.ophtha.2019.10.019
   PubMed Web of Science ®Google Scholar
• Sadda SR, Campbell J, Dugel PU, et al. Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: a post hoc analysis of Protocol I data. Eye. 2020;34(3):480–490. doi:10.1038/s41433-019-0522-z
   PubMed Web of Science ®Google Scholar
• Browning DJ, Stewart MW, Lee C. Diabetic macular edema: evidence-based management. Indian J Ophthalmol. 2018;66(12):1736–1750. doi:10.4103/ijo.IJO_1240_18
   PubMed Web of Science ®Google Scholar
• Rosenblatt BJ, Shah GK, Sharma S, Bakal J. Pars plana vitrectomy with internal limiting membranectomy for refractory diabetic macular edema without a taut posterior hyaloid. Graefes Arch Clin Exp Ophthalmol. 2005;243(1):20–25. doi:10.1007/s00417-004-0958-z
   Web of Science ®Google Scholar
• Patel JI, Hykin PG, Schadt M, Luong V, Fitzke F, Gregor ZJ. Pars plana vitrectomy for diabetic macular oedema: OCT and functional correlations. Eye. 2006;20(6):674–680. doi:10.1038/sj.eye.6701945
   Web of Science ®Google Scholar
• Maturi RK, Glassman AR, Liu D, et al.; Diabetic Retinopathy Clinical Research Network. Effect of Adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a drcr network phase 2 randomized clinical trial. JAMA Ophthalmol. 2018;136(1):29–38. doi:10.1001/jamaophthalmol.2017.4914.
   PubMed Web of Science ®Google Scholar
• Bressler NM, Beaulieu WT, Glassman AR, et al.; Diabetic Retinopathy Clinical Research Network. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136(3):257–269. doi:10.1001/jamaophthalmol.2017.6565.
   PubMed Web of Science ®Google Scholar
• Chen YP, Wu AL, Chuang CC, Chen SN. Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases. Sci Rep. 2019;9(1):10952. doi:10.1038/s41598-019-47241-1
   PubMed Web of Science ®Google Scholar
• National cancer institute dictionary of cancer terms. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/prognostic-factor. Accessed May 13, 2021.
   Google Scholar
• Haritoglou C, Maier M, Neubauer AS, Augustin AJ. Current concepts of pharmacotherapy of diabetic macular edema. Expert Opin Pharmacother. 2020;21(4):467–475. doi:10.1080/14656566.2020.1713093
   PubMed Web of Science ®Google Scholar
• Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol. 1999;127(6):688–693. doi:10.1016/S0002-9394(99)00033-1
   PubMed Web of Science ®Google Scholar
• Kim BY, Smith SD, Kaiser PK. Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol. 2006;142(3):405–412. doi:10.1016/j.ajo.2006.04.023
   PubMed Web of Science ®Google Scholar
• Sonoda S, Sakamoto T, Yamashita T, Shirasawa M, Otsuka H, Sonoda Y. Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema. Retina. 2014;34(4):741–748. doi:10.1097/IAE.0b013e3182a48917
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay S, Bandyopadhyay SK, Saha M, Sinha A. Study of aqueous cytokines in patients with different patterns of diabetic macular edema based on optical coherence tomography. Int Ophthalmol. 2018;38(1):241–249. doi:10.1007/s10792-017-0453-2
   Web of Science ®Google Scholar
• Yenihayat F, Özkan B, Kasap M, et al. Vitreous IL-8 and VEGF levels in diabetic macular edema with or without subretinal fluid. Int Ophthalmol. 2019;39(4):821–828. doi:10.1007/s10792-018-0874-6
   PubMed Web of Science ®Google Scholar
• Tsai MJ, Hsieh YT, Shen EP, Peng YJ. Systemic associations with residual subretinal fluid after ranibizumab in diabetic macular edema. J Ophthalmol. 2017;2017:4834201. doi:10.1155/2017/4834201
   PubMed Web of Science ®Google Scholar
• Turgut B, Gul FC, Ilhan N, Demir T, Celiker U. Comparison of serum glycosylated hemoglobin levels in patients with diabetic cystoid macular edema with and without serous macular detachment. Indian J Ophthalmol. 2010;58(5):381–384.
   Web of Science ®Google Scholar
• Sophie R, Lu N, Campochiaro PA. Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Ophthalmology. 2015;122(7):1395–1401. doi:10.1016/j.ophtha.2015.02.036
   PubMed Web of Science ®Google Scholar
• Fickweiler W, Schauwvlieghe AME, Schlingemann RO; BRDME Research Group. Predictive value of optical coherence tomographic features in the Bevacizumab and Ranibizumab in patients with Diabetic Macular Edema (BRDME) sTUDY. Retina. 2018;38(4):812–819. doi:10.1097/IAE.0000000000001626
   Web of Science ®Google Scholar
• Shimura M, Yasuda K, Yasuda M, Nakazawa T. Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema. Retina. 2013;33(4):740–747. doi:10.1097/IAE.0b013e31826b6763
   Web of Science ®Google Scholar
• Kaya M, Karahan E, Ozturk T, Kocak N, Kaynak S. Effectiveness of intravitreal ranibizumab for diabetic macular edema with serous retinal detachment. Korean J Ophthalmol. 2018;32(4):296–302. doi:10.3341/kjo.2017.0117
   Google Scholar
• Hwang HB, Jee D, Kwon JW. Characteristics of diabetic macular edema patients with serous retinal detachment. Medicine. 2019;98(51):e18333. doi:10.1097/MD.0000000000018333
   Web of Science ®Google Scholar
• Castro-Navarro V, Cervera-Taulet E, Navarro-Palop C, Monferrer-Adsuara C, Hernández-Bel L, Montero-Hernández J. Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema. BMC Ophthalmol. 2019;19(1):15.
   PubMed Web of Science ®Google Scholar
• Spaide RF. Retinal vascular cystoid macular edema: review and new theory. Retina. 2016;36(10):1823–1842. doi:10.1097/IAE.0000000000001158
   PubMed Web of Science ®Google Scholar
• Sacconi R, Lutty GA, Mullins RF, Borrelli E, Bandello F, Querques G. Subretinal pseudocysts: a novel OCT finding in diabetic macular edema. Am J Ophthalmol Case Rep. 2019;16:100567. doi:10.1016/j.ajoc.2019.100567
   Google Scholar
• Yamamoto S, Yamamoto T, Hayashi M, Takeuchi S. Morphological and functional analyses of diabetic macular edema by optical coherence tomography and multifocal electroretinograms. Graefes Arch Clin Exp Ophthalmol. 2001;239(2):96–101. doi:10.1007/s004170000238
   Web of Science ®Google Scholar
• Bezzina AD, Carbonaro F. Factors Predicting treatment response in anti-vascular endothelial growth factor naïve diabetic macular edema patients treated with intravitreal bevacizumab. J Ocul Pharmacol Ther. 2019;35(10):551–557. doi:10.1089/jop.2018.0112
   PubMed Web of Science ®Google Scholar
• De Benedetto U, Sacconi R, Pierro L, Lattanzio R, Bandello F. Optical coherence tomographic hyperreflective foci in early stages of diabetic retinopathy. Retina. 2015;35(3):449–453. doi:10.1097/IAE.0000000000000336
   Web of Science ®Google Scholar
• Chatziralli IP, Sergentanis TN, Sivaprasad S. Hyperreflective foci as an independent visual outcome predictor in macular edema due to retinal vascular diseases treated with intravitreal dexamethasone or ranibizumab. Retina. 2016;36(12):2319–2328. doi:10.1097/IAE.0000000000001070
   PubMed Web of Science ®Google Scholar
• Hwang HS, Chae JB, Kim JY, Kim DY. Association between hyperreflective dots on spectral-domain optical coherence tomography in macular edema and response to treatment. Invest Ophthalmol Vis Sci. 2017;58(13):5958–5967. doi:10.1167/iovs.17-22725
   PubMed Web of Science ®Google Scholar
• Schreur V, Altay L, van Asten F, et al. Hyperreflective foci on optical coherence tomography associate with treatment outcome for anti-VEGF in patients with diabetic macular edema. PLoS One. 2018;13(10):e0206482. doi:10.1371/journal.pone.0206482
   PubMed Web of Science ®Google Scholar
• Vujosevic S, Torresin T, Bini S, et al. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema. Acta Ophthalmol. 2017;95(5):464–471. doi:10.1111/aos.13294
   PubMed Web of Science ®Google Scholar
• Sun JK, Lin MM, Lammer J, et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol. 2014;132(11):1309–1316. doi:10.1001/jamaophthalmol.2014.2350
   PubMed Web of Science ®Google Scholar
• Das R, Spence G, Hogg RE, Stevenson M, Chakravarthy U. Disorganization of inner retina and outer retinal morphology in diabetic macular edema. JAMA Ophthalmol. 2018;136(2):202–208. doi:10.1001/jamaophthalmol.2017.6256
   PubMed Web of Science ®Google Scholar
• Radwan SH, Soliman AZ, Tokarev J, Zhang L, van Kuijk FJ, Koozekanani DD. Association of disorganization of retinal inner layers with vision after resolution of center-involved diabetic macular edema. JAMA Ophthalmol. 2015;133(7):820–825. doi:10.1001/jamaophthalmol.2015.0972
   PubMed Web of Science ®Google Scholar
• Zur D, Iglicki M, Sala-Puigdollers A, et al.; International Retina Group (IRG). Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant. Acta Ophthalmol. 2020;98(2):e217–e223. doi:10.1111/aos.14230.
   PubMed Web of Science ®Google Scholar
• Yanyali A, Bozkurt KT, Macin A, Horozoglu F, Nohutcu AF. Quantitative assessment of photoreceptor layer in eyes with resolved edema after pars plana vitrectomy with internal limiting membrane removal for diabetic macular edema. Ophthalmologica. 2011;226(2):57–63. doi:10.1159/000327597
   Web of Science ®Google Scholar
• Shin HJ, Lee SH, Chung H, Kim HC. Association between photoreceptor integrity and visual outcome in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2012;250(1):61–70. doi:10.1007/s00417-011-1774-x
   PubMed Web of Science ®Google Scholar
• Muftuoglu IK, Mendoza N, Gaber R, Alam M, You Q, Freeman WR. Integrity of outer retinal layers after resolution of central involved diabetic macular edema. Retina. 2017;37(11):2015–2024. doi:10.1097/IAE.0000000000001459
   PubMed Web of Science ®Google Scholar
• Rangaraju L, Jiang X, McAnany JJ, et al. Association between visual acuity and retinal layer metrics in diabetics with and without macular edema. J Ophthalmol. 2018;2018:1089043.
   Web of Science ®Google Scholar
• Wong RL, Lee JW, Yau GS, Wong IY. Relationship between outer retinal layers thickness and visual acuity in diabetic macular edema. Biomed Res Int. 2015;2015:981471. doi:10.1155/2015/981471
   Web of Science ®Google Scholar
• Eliwa TF, Hussein MA, Zaki MA, Raslan OA. Outer retinal layer thickness as good visual predictor in patients with diabetic macular edema. Retina. 2018;38(4):805–811. doi:10.1097/IAE.0000000000001599
   Web of Science ®Google Scholar
• Abd Elhamid AH. Quantitative assessment of outer retinal layer and photoreceptor outer segment layer and their relation to visual acuity in diabetic macular edema. J Ophthalmol. 2019;2019:8216150. doi:10.1155/2019/8216150
   Web of Science ®Google Scholar
• Hatz K, Ebneter A, Tuerksever C, Pruente C, Zinkernagel M. Repeated dexamethasone intravitreal implant for the treatment of diabetic macular oedema unresponsive to anti-VEGF therapy: outcome and predictive SD-OCT features. Ophthalmologica. 2018;239(4):205–214. doi:10.1159/000485852
   PubMed Web of Science ®Google Scholar
• Castro-Navarro V, Monferrer-Adsuara C, Navarro-Palop C, Montero-Hernández J, Cervera-Taulet E. Effect of dexamethasone intravitreal implant on visual acuity and foveal photoreceptor integrity in macular edema secondary to retinal vascular disease. Ophthalmologica. 2021;244(1):83–92. doi:10.1159/000512195
   PubMed Web of Science ®Google Scholar
• Jain A, Saxena S, Khanna VK, Shukla RK, Meyer CH. Status of serum VEGF and ICAM-1 and its association with external limiting membrane and inner segment-outer segment junction disruption in type 2 diabetes mellitus. Mol Vis. 2013;19:1760–1768.
   PubMed Web of Science ®Google Scholar
• De S, Saxena S, Kaur A, et al. Sequential restoration of external limiting membrane and ellipsoid zone after intravitreal anti-VEGF therapy in diabetic macular oedema. Eye. 2021;35(5):1490–1495. doi:10.1038/s41433-020-1100-0
   Web of Science ®Google Scholar
• Bansal P, Agarwal A, Gupta V, Singh R, Gupta A. Spectral domain optical coherence tomography changes following intravitreal dexamethasone implant, Ozurdex® in patients with uveitic cystoid macular edema. Indian J Ophthalmol. 2015;63(5):416–422. doi:10.4103/0301-4738.159870
   PubMed Web of Science ®Google Scholar
• Altunel O, Duru N, Goktas A, Ozkose A, Goktas E, Atas M. Evaluation of foveal photoreceptor layer in eyes with macular edema associated with branch retinal vein occlusion after ozurdex treatment. Int Ophthalmol. 2019;2019(2):333–339. doi:10.1007/s10792-016-0261-0
   Web of Science ®Google Scholar
• Iacono P, Parodi MB, Scaramuzzi M, Bandello F. Morphological and functional changes in recalcitrant diabetic macular oedema after intravitreal dexamethasone implant. Br J Ophthalmol. 2017;101(6):791–795. doi:10.1136/bjophthalmol-2016-308726
   PubMed Web of Science ®Google Scholar
• Bonfiglio V, Reibaldi M, Pizzo A, et al. Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers. Acta Ophthalmol. 2019;97(4):e540–e544. doi:10.1111/aos.13935
   PubMed Web of Science ®Google Scholar
• Chen Y, Li J, Yan Y, Shen X. Diabetic macular morphology changes may occur in the early stage of diabetes. BMC Ophthalmol. 2016;16:12. doi:10.1186/s12886-016-0186-4
   PubMed Web of Science ®Google Scholar
• Wanek J, Blair NP, Chau FY, Lim JI, Leiderman YI, Shahidi M. Alterations in retinal layer thickness and reflectance at different stages of diabetic retinopathy by en face optical coherence tomography. Invest Ophthalmol Vis Sci. 2016;57(9):OCT341–347. doi:10.1167/iovs.15-18715
   Web of Science ®Google Scholar
• Huang XL, Song YP, Ding Q, Chen X, Hong L. Evaluation of outer retinal tubulations in diabetic macular edema underwent anti-VEGF treatment. Int J Ophthalmol. 2019;12(3):442–450. doi:10.18240/ijo.2019.03.15
   Web of Science ®Google Scholar
• Fonollosa A, Zarranz-Ventura J, Valverde A, et al. Predictive capacity of baseline hyperreflective dots on the intravitreal dexamethasone implant (Ozurdex®) outcomes in diabetic macular edema: a multicenter study. Graefes Arch Clin Exp Ophthalmol. 2019;257(11):2381–2390. doi:10.1007/s00417-019-04446-4
   PubMed Web of Science ®Google Scholar
• Lee H, Jang H, Choi YA, Kim HC, Chung H. Association between soluble CD14 in the aqueous humor and hyperreflective foci on optical coherence tomography in patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2018;59(2):715–721. doi:10.1167/iovs.17-23042
   PubMed Web of Science ®Google Scholar
• Jonas JB, Jonas RA, Neumaier M, Findeisen P. Cytokine concentration in aqueous humor of eyes with diabetic macular edema. Retina. 2012;32(10):2150–2157. doi:10.1097/IAE.0b013e3182576d07
   PubMed Web of Science ®Google Scholar
• Lafuma A, Brézin A, Lopatriello S, et al. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK. Pharmacoeconomics. 2006;24(2):193–205. doi:10.2165/00019053-200624020-00007
   PubMed Web of Science ®Google Scholar
• Abraldes MJ, Pareja A, Roura M; En representación del grupo del estudio OBSERVAR. Analysis of costs associated with the management and morbidity of diabetic macular oedema and macular oedema secondary to retinal vein occlusion. Arch Soc Esp Oftalmol. 2016;91(6):273–280. doi:10.1016/j.oftal.2015.11.019
   Google Scholar
• Romero-Aroca P, de la Riva-fernandez S, Valls-Mateu A, et al. Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up. BMC Ophthalmol. 2016;16:136. doi:10.1186/s12886-016-0318-x
   Web of Science ®Google Scholar